

## Special Issue

# Clinical and Translational Research in Head and Neck Cancer

### Message from the Guest Editor

Head and neck cancer encompass multiple histologic tumors that can represent the breadth of most human cancer, and their unique occurrences in the face/scalp and the upper digestive tracts to include the sinonasal tracts, oral cavity, oropharynx, larynx, and cervical esophagus provide unique challenges for scientists and clinicians. Although there are now new approved drugs for many of these tumor types, there are still important clinical concerns for weighing oncologic cure and functional preservation. Hence, incorporation of a new modalities, such as immunotherapy and targeted biologics, will require basic, clinical, and translational research for optimal patient care that incorporates locoregional recurrence, overall survival, and quality of life maintenance. This Special Issue presents some of these recent advances in oncologic therapeutics in head and neck cancer patients to promote future translational and clinical studies.

---

### Guest Editor

Dr. Young J. Kim

Chair Oncology, Global Development Scientific Council, Regeneron Pharmaceuticals, New York, NY, USA

---

### Deadline for manuscript submissions

closed (20 May 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/137637](https://mdpi.com/si/137637)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)